Agios Pharmaceuticals Inc
NASDAQ:AGIO
Intrinsic Value
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. [ Read More ]
The intrinsic value of one AGIO stock under the Base Case scenario is 27.17 USD. Compared to the current market price of 29.53 USD, Agios Pharmaceuticals Inc is Overvalued by 8%.
Valuation Backtest
Agios Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling AGIO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Agios Pharmaceuticals Inc
Current Assets | 833.8m |
Cash & Short-Term Investments | 776.9m |
Receivables | 2.8m |
Other Current Assets | 54.1m |
Non-Current Assets | 103.3m |
Long-Term Investments | 29.4m |
PP&E | 69.8m |
Other Non-Current Assets | 4.1m |
Current Liabilities | 68m |
Accounts Payable | 9.8m |
Accrued Liabilities | 58.2m |
Non-Current Liabilities | 58.1m |
Other Non-Current Liabilities | 58.1m |
Earnings Waterfall
Agios Pharmaceuticals Inc
Revenue
|
26.8m
USD
|
Cost of Revenue
|
-2.9m
USD
|
Gross Profit
|
23.9m
USD
|
Operating Expenses
|
-415.4m
USD
|
Operating Income
|
-391.5m
USD
|
Other Expenses
|
39.4m
USD
|
Net Income
|
-352.1m
USD
|
Free Cash Flow Analysis
Agios Pharmaceuticals Inc
What is Free Cash Flow?
AGIO Profitability Score
Profitability Due Diligence
Agios Pharmaceuticals Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
Agios Pharmaceuticals Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
AGIO Solvency Score
Solvency Due Diligence
Agios Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Score
Agios Pharmaceuticals Inc's solvency score is 74/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AGIO Price Targets Summary
Agios Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for AGIO is 43.66 USD with a low forecast of 29.29 USD and a high forecast of 51.45 USD.
Ownership
AGIO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
AGIO Price
Agios Pharmaceuticals Inc
Average Annual Return | -16.3% |
Standard Deviation of Annual Returns | 6.79% |
Max Drawdown | -72% |
Market Capitalization | 1.7B USD |
Shares Outstanding | 56 194 800 |
Percentage of Shares Shorted | 11.89% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 390 full-time employees. The company went IPO on 2013-07-24. The firm's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The firm is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.
Contact
IPO
Employees
Officers
The intrinsic value of one AGIO stock under the Base Case scenario is 27.17 USD.
Compared to the current market price of 29.53 USD, Agios Pharmaceuticals Inc is Overvalued by 8%.